Pennsylvania stops GLP‑1 coverage
Pennsylvania Medicaid has stopped covering GLP‑1 weight‑loss drugs for obesity after program costs ballooned from $233 million to $1.3 billion over three years, a move that dramatically reshapes access for low‑income patients. The decision highlights how state budgets are reacting to rapid uptake and sticker shock for these medicines. (inquirer.com)
Pennsylvania’s Medicaid program stopped paying for weight-loss use of drugs like Wegovy and Zepbound on January 1, 2026, after the state said spending on these medicines jumped from $233 million in 2022 to about $1.3 billion in 2025. (pa.gov, msn.com) The cutoff is narrower than it sounds: Pennsylvania will still cover these drugs when a doctor shows they are being used for diabetes or another covered condition, but not for obesity alone in adults 21 and older. (pa.gov, phlp.org, healthpartnersplans.com) These drugs became a budget shock because Pennsylvania only started covering glucagon-like peptide-1 medicines for obesity in January 2023, and the monthly list prices for brand-name versions can run around $1,000 or more. (pa.gov, kff.org) By 2025, the state said these drugs had grown from 5% of Pennsylvania Medicaid drug spending to 22%, while total Medicaid pharmacy spending rose from $4.8 billion to $6 billion. (msn.com) Pennsylvania had been one of a relatively small group of states willing to cover obesity use of these drugs in Medicaid, because federal law does not require states to pay for weight-loss medicines. (msn.com, pa.gov) That optional status is the key to the whole fight: if a state covers insulin for diabetes, it is meeting a core Medicaid need, but if it covers Wegovy for obesity, it is choosing to add a benefit that can swell fast when demand spikes. (pa.gov, kff.org) Patients already taking the drugs had to get new prior approval after December 31, 2025, and plans told members they could not refill unless a doctor documented another covered reason for treatment. (healthpartnersplans.com, phlp.org) Pennsylvania did not ban every obesity medicine. The state said non-glucagon-like peptide-1 obesity drugs that are on its preferred drug list can still remain covered, which means the cut is aimed at the newest and most expensive class. (pa.gov) The hard part for patients is that glucagon-like peptide-1 drugs often work only while people stay on them, so losing coverage can mean weight returns after the prescription stops. (nejm.org, nih.gov) What happened in Pennsylvania is likely to be copied elsewhere, because governors and Medicaid directors are looking at the same math: a drug can be clinically effective, popular with patients, and still too expensive for a state budget if tens of thousands of people qualify at once. (kff.org, whyy.org)
